Variantyx, a Framingham, MA-based company which specialises in molecular diagnostics, raised $36M in funding.
Backers included Peregrine Ventures, Pitango HealthTech, New Era Capital Partners and Bosch Ventures. The round brought the total amount invested in Variantyx to over $125M.
The company intends to use the funds for additional technological and commercial expansion, seizing the opportunity to provide genome-based care to a larger number of patients.
Led by CEO Haim Neerman, Variantyx is a technology-driven molecular diagnostics company providing solutions for the genetic disorders, reproductive health, and precision oncology markets. The proprietary whole genome analysis platforms developed by Variantyx allow clinicians to understand a person’s genetic makeup, leading to enhanced diagnostic capabilities and improved personalized treatment recommendations.
FinSMEs
29/04/2024